<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44553">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526290</url>
  </required_header>
  <id_info>
    <org_study_id>OCUN-010</org_study_id>
    <nct_id>NCT02526290</nct_id>
  </id_info>
  <brief_title>Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator</brief_title>
  <official_title>Single-Arm, Multicenter, Open-Label Study to Evaluate the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Participants With Aqueous Tear Deficient Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oculeve, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oculeve, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal
      Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be
      evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, multicenter, open-label clinical trial in which
      participants will use the Oculeve Intranasal Lacrimal Neurostimulator to stimulate tear
      production for 180 days. Participants will have a Screening Visit within 60 days prior to
      the initial device application. Device application will be initiated at Day 0, at which time
      participants will receive training on the proper use of the device. Participants will
      receive follow-up visits at Days 7, 30, 90 and 180.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stimulated acute tear production</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corrected distance visual acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit lamp biomicroscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Device-related adverse events</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>Active - Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intranasal Lacrimal Neurostimulator (Oculeve)</intervention_name>
    <description>Neurostimulation device</description>
    <arm_group_label>Active - Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with moderate to severe dry eye disease

          -  Literate, able to speak English or Spanish, and able to complete questionnaires
             independently

          -  Willing to sign the informed consent and deemed capable of complying with the
             requirements of the study protocol

        Exclusion Criteria:

          -  Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in
             the opinion of the investigator, may lead to clinically significant increased
             bleeding

          -  Nasal or sinus surgery (including history of application of nasal cautery) or
             significant trauma

          -  Cardiac demand pacemaker, implanted defibrillator or other implanted electronic
             device

          -  Diagnosis of epilepsy

          -  Corneal transplant in either or both eyes

          -  Participation in any clinical trial with a new active substance or a new device
             within 30 days of the Screening Visit

          -  Women who are pregnant, planning a pregnancy, or nursing at the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Holland, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cincinnati Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornea &amp; Cataract Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 1, 2016</lastchanged_date>
  <firstreceived_date>August 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
